The importance of ErbB3 expression in breast cancer has been recently highlighted by the demonstration that continued oncogenic signalling through ErbB3 in human breast cancer cell lines results in the failure of gefitinib to completely inhibit the kinase activity of ErbB2 (Sergina et al, 2007). The gene discussed is ERBB2; the disease is breast cancer.